1. Hapke, D.M., Stegmann, A.P. & Mitchell, B.S. Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Cancer Res. 56, 2343–2347 (1996).
2. Owens, J.K., Shewach, D.S., Ullman, B. & Mitchell, B.S. Resistance to 1-β-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res. 52, 2389–2393 (1992).
3. Ruiz van Haperen, V.W. et al. Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res. 54, 4138–4143 (1994).
4. Stegmann, A.P., Honders, W.H., Willemze, R., Ruiz van Haperen, V.W. & Landegent, J.E. Transfection of wild-type deoxycytidine kinase (dCK) cDNA into an AraC- and DAC-resistant rat leukemic cell line of clonal origin fully restores drug sensitivity. Blood 85, 1188–1194 (1995).
5. Blackstock, A.W. et al. Tumor uptake and elimination of 2′,2′-difluoro-2′-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response. Clin. Cancer Res. 7, 3263–3268 (2001).